Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

PI3K Catalytic Subunits α and β Modulate Cell Death and IL-6 Secretion Induced by Talc Particles in Human Lung Carcinoma Cells.

Bougen-Zhukov NM, Lee YY, Lee JJ, Lee P, Loo LH.

Am J Respir Cell Mol Biol. 2019 Sep 12. doi: 10.1165/rcmb.2019-0050OC. [Epub ahead of print]

PMID:
31513749
2.

Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.

Lumachi F, Mazza F, Ermani M, Chiara GB, Basso SM.

Anticancer Res. 2012 Nov;32(11):5071-4.

PMID:
23155281
3.

Interventions for the management of malignant pleural effusions: a network meta-analysis.

Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N.

Cochrane Database Syst Rev. 2016 May 8;(5):CD010529. doi: 10.1002/14651858.CD010529.pub2. Review.

4.

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.

Verma A, Chopra A, Lee YW, Bharwani LD, Asmat AB, Aneez DB, Akbar FA, Lim AY, Chotirmall SH, Abisheganaden J.

Curr Drug Discov Technol. 2016;13(2):68-76.

5.

Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.

Korsic M, Badovinac S, Cucevic B, Janevski Z.

Wien Klin Wochenschr. 2015 Dec;127(23-24):963-9. doi: 10.1007/s00508-015-0716-8. Epub 2015 Apr 10.

PMID:
25860847
6.

Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis.

Fysh ET, Thomas R, Read CA, Kwan BC, Yap E, Horwood FC, Lee P, Piccolo F, Shrestha R, Garske LA, Lam DC, Rosenstengel A, Bint M, Murray K, Smith NA, Lee YC.

BMJ Open. 2014 Nov 6;4(11):e006757. doi: 10.1136/bmjopen-2014-006757. Erratum in: BMJ Open. 2015;5(5):e006757corr1. Lam, Ben C H [corrected to Kwan, Ben C H].

7.

Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.

Kolschmann S, Ballin A, Gillissen A.

Chest. 2005 Sep;128(3):1431-5.

PMID:
16162739
8.

The dynamics of selected local inflammatory markers to talc in the treatment of malignant pleural effusions.

Habal P, Jankovicova K, Omran N, Kondelkova K, Krejsek J, Mandak J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Dec;157(4):311-5. doi: 10.5507/bp.2012.095. Epub 2012 Dec 7.

9.

An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion.

Beck TN, Deneka AY, Chai L, Kanach C, Johal P, Alvarez NJ, Boumber Y, Golemis EA, Laub GW.

BMC Cancer. 2019 Jun 24;19(1):614. doi: 10.1186/s12885-019-5777-z.

10.

Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases.

Sanchez-Armengol A, Rodriguez-Panadero F.

Chest. 1993 Nov;104(5):1482-5.

PMID:
8222811
11.

Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan.

Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S.

Jpn J Clin Oncol. 2018 Apr 1;48(4):376-381. doi: 10.1093/jjco/hyy020.

PMID:
29528450
12.

[Treatment of malignant pleural effusion by pleurodesis with talc].

Filippetti M, Crucitti G, Vanni B, Della Giulia M, Foggi P, Del Monte G.

Chir Ital. 2000 Sep-Oct;52(5):541-7. Italian.

PMID:
11190547
13.

Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis.

Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, Loddenkemper R.

Chest. 2004 Nov;126(5):1522-8.

PMID:
15539722
14.

Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial.

Kleontas A, Sioga A, Pandria N, Barbetakis N, Lazopoulos A, Katsikas I, Asteriou C, Paliouras D, Kamperis E, Ikonomou D, Papamitsou T, Filippou D, Destouni C, Ikonomou L, Zarogoulidis K, Papagiannopoulos K.

J Thorac Dis. 2019 May;11(5):1788-1798. doi: 10.21037/jtd.2019.05.25.

15.

Pleurodesis for malignant pleural effusions.

Shaw P, Agarwal R.

Cochrane Database Syst Rev. 2004;(1):CD002916. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD002916.

PMID:
14973997
16.

Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis.

Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, Digón-Pereiras J, Rodriguez-Panadero F.

Eur Respir J. 2010 Jan;35(1):160-6. doi: 10.1183/09031936.00146808. Epub 2009 Jul 2.

17.

Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles.

Genofre EH, Vargas FS, Acencio MM, Antonangelo L, Teixeira LR, Marchi E.

Respir Med. 2009 Jan;103(1):91-7. doi: 10.1016/j.rmed.2008.07.021. Epub 2008 Sep 11.

18.

Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.

Basso SM, Mazza F, Marzano B, Santeufemia DA, Chiara GB, Lumachi F.

Anticancer Res. 2012 Nov;32(11):5131-4.

PMID:
23155293
19.

Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.

Yildirim H, Metintas M, Ak G, Metintas S, Erginel S.

Lung Cancer. 2008 Oct;62(1):139-44. doi: 10.1016/j.lungcan.2008.02.017. Epub 2008 Apr 9.

PMID:
18403045
20.

A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions.

Ong KC, Indumathi V, Raghuram J, Ong YY.

Respirology. 2000 Jun;5(2):99-103.

PMID:
10894097

Supplemental Content

Support Center